Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Partially mismatched blood cell transplants for high-risk hematologic malignancy.
Russell JA, Desai S, Herbut B, Brown C, Luider J, Ruether JD, Stewart D, Chaudhry A, Booth K, Jorgenson K, Coppes MJ, Turner AR, Larratt L, Poon MC, Klassen J. Russell JA, et al. Among authors: larratt l. Bone Marrow Transplant. 1997 May;19(9):861-6. doi: 10.1038/sj.bmt.1700757. Bone Marrow Transplant. 1997. PMID: 9156258
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, Quinlan D, Stewart D. Russell JA, et al. Among authors: larratt l. Biol Blood Marrow Transplant. 2007 Mar;13(3):299-306. doi: 10.1016/j.bbmt.2006.10.017. Biol Blood Marrow Transplant. 2007. PMID: 17317583 Free article. Clinical Trial.
Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA, Duan Q, Chaudhry MA, Savoie ML, Balogh A, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA. Russell JA, et al. Among authors: larratt l. Biol Blood Marrow Transplant. 2008 Aug;14(8):888-95. doi: 10.1016/j.bbmt.2008.05.010. Biol Blood Marrow Transplant. 2008. PMID: 18640572 Free article. Clinical Trial.
Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome.
Russell JA, Larratt L, Brown C, Turner AR, Chaudhry A, Booth K, Woodman RC, Wolff J, Valentine K, Stewart D, Ruether JD, Ruether BA, Klassen J, Jones AR, Gyonyor E, Egeler M, Dunsmore J, Desai S, Coppes MJ, Bowen T, Anderson R, Poon MC. Russell JA, et al. Among authors: larratt l. Bone Marrow Transplant. 1999 Dec;24(11):1177-83. doi: 10.1038/sj.bmt.1702051. Bone Marrow Transplant. 1999. PMID: 10642805 Clinical Trial.
Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis.
Duggan P, Booth K, Chaudhry A, Stewart D, Ruether JD, Glück S, Morris D, Brown CB, Herbut B, Coppes M, Anderson R, Wolff J, Egeler M, Desai S, Turner AR, Larratt L, Gyonyor E, Russell JA; Alberta Blood and Bone Marrow Transplant Program. Duggan P, et al. Among authors: larratt l. Bone Marrow Transplant. 2002 Nov;30(10):681-6. doi: 10.1038/sj.bmt.1703674. Bone Marrow Transplant. 2002. PMID: 12420207
Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG.
El Kourashy S, Williamson T, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Yang M, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA, Russell JA. El Kourashy S, et al. Among authors: larratt l. Bone Marrow Transplant. 2011 Aug;46(8):1077-83. doi: 10.1038/bmt.2010.257. Epub 2010 Nov 8. Bone Marrow Transplant. 2011. PMID: 21057555
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.
Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Stewart DA. Russell JA, et al. Among authors: larratt l. Biol Blood Marrow Transplant. 2007 Jul;13(7):814-21. doi: 10.1016/j.bbmt.2007.03.003. Epub 2007 Apr 23. Biol Blood Marrow Transplant. 2007. PMID: 17580259 Free article.
69 results